D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 119 Citations 63,134 775 World Ranking 1606 National Ranking 53

Research.com Recognitions

Awards & Achievements

2011 - German National Academy of Sciences Leopoldina - Deutsche Akademie der Naturforscher Leopoldina – Nationale Akademie der Wissenschaften Internal Medicine and Dermatology

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Gene

His primary areas of investigation include Internal medicine, Chronic lymphocytic leukemia, Fludarabine, Surgery and Immunology. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Oncology. In his research, Bioinformatics, Mutation, Cancer research and Lung cancer is intimately related to Cancer, which falls under the overarching field of Oncology.

His Chronic lymphocytic leukemia study improves the overall literature in Leukemia. His work focuses on many connections between Fludarabine and other disciplines, such as Bendamustine, that overlap with his field of interest in Refractory Chronic Lymphocytic Leukemia. Michael Hallek works mostly in the field of Immunology, limiting it down to topics relating to Cytotoxic T cell and, in certain cases, FOXP3, Interleukin 2 and Cancer immunotherapy.

His most cited work include:

  • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines (2519 citations)
  • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial (1433 citations)
  • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. (1170 citations)

What are the main themes of his work throughout his whole career to date?

Michael Hallek mostly deals with Internal medicine, Chronic lymphocytic leukemia, Oncology, Immunology and Cancer research. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Surgery. His Chronic lymphocytic leukemia study results in a more complete grasp of Leukemia.

He interconnects Venetoclax, Idelalisib, Obinutuzumab and Transplantation in the investigation of issues within Oncology. His research in Cancer research intersects with topics in Apoptosis, breakpoint cluster region, Tyrosine kinase and CD40. His study in Fludarabine is interdisciplinary in nature, drawing from both Regimen, Alemtuzumab, Progression-free survival and [email protected]

He most often published in these fields:

  • Internal medicine (49.24%)
  • Chronic lymphocytic leukemia (36.20%)
  • Oncology (29.96%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (49.24%)
  • Chronic lymphocytic leukemia (36.20%)
  • Oncology (29.96%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Chronic lymphocytic leukemia, Oncology, Venetoclax and Cancer research. His Obinutuzumab, Rituximab, Ibrutinib and Chemoimmunotherapy study in the realm of Internal medicine connects with subjects such as In patient. In his study, which falls under the umbrella issue of Chronic lymphocytic leukemia, Neutropenia is strongly linked to Gastroenterology.

His studies in Oncology integrate themes in fields like Idelalisib, Clinical trial, Chemotherapy, Stage and Comorbidity. His work deals with themes such as Progression-free survival and Tumor lysis syndrome, which intersect with Venetoclax. Michael Hallek has included themes like Cancer, Phenotype, Tyrosine kinase, B cell and Monoclonal antibody in his Cancer research study.

Between 2017 and 2021, his most popular works were:

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (392 citations)
  • Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions (205 citations)
  • COVID-19 associated pulmonary aspergillosis. (157 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

Michael Hallek mainly focuses on Internal medicine, Chronic lymphocytic leukemia, Oncology, Venetoclax and Cancer research. As part of his studies on Internal medicine, he often connects relevant areas like Gastroenterology. He combines subjects such as MEDLINE and Minimal residual disease with his study of Chronic lymphocytic leukemia.

His Oncology research includes elements of Cancer, Chemotherapy, Chemoimmunotherapy, [email protected] and Stage. His research investigates the connection between Venetoclax and topics such as Progression-free survival that intersect with problems in Randomized controlled trial and Hazard ratio. His Cancer research research incorporates elements of Cell culture, Autocrine signalling and B-cell receptor, B cell.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio.
Blood (2008)

4108 Citations

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek;K. Fischer;Gunter Fingerle-Rowson;Anne Michelle Fink.
The Lancet (2010)

2061 Citations

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson.
The New England Journal of Medicine (2014)

1737 Citations

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Valentin Goede;Kirsten Fischer;Raymonde Busch;Anja Engelke.
The New England Journal of Medicine (2014)

1457 Citations

Comprehensive genomic profiles of small cell lung cancer

Julie George;Jing Shan Lim;Se Jin Jang;Yupeng Cun.
Nature (2015)

1100 Citations

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

Martin Peifer;Lynnette Fernández-Cuesta;Martin L. Sos;Julie George.
Nature Genetics (2012)

1064 Citations

Real-time single-molecule imaging of the infection pathway of an adeno-associated virus.

Georg Seisenberger;Martin U. Ried;Thomas Endreß;Hildegard Büning.
Science (2001)

1009 Citations

Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process

M Hallek;P L Bergsagel;K C Anderson.
Blood (1998)

967 Citations

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

Jonathan Weiss;Martin L. Sos;Danila Seidel;Martin Peifer.
Science Translational Medicine (2010)

869 Citations

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Barbara F. Eichhorst;Raymonde Busch;Georg Hopfinger;Rita Pasold.
Blood (2005)

847 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Michael Hallek

John C. Byrd

John C. Byrd

University of Cincinnati

Publications: 220

Susan O'Brien

Susan O'Brien

University of California, Irvine

Publications: 198

William G. Wierda

William G. Wierda

The University of Texas MD Anderson Cancer Center

Publications: 171

Jennifer R. Brown

Jennifer R. Brown

Harvard University

Publications: 158

Michael J. Keating

Michael J. Keating

The University of Texas MD Anderson Cancer Center

Publications: 152

Gianluca Gaidano

Gianluca Gaidano

University of Eastern Piedmont Amadeo Avogadro

Publications: 150

Tadeusz Robak

Tadeusz Robak

Medical University of Lodz

Publications: 146

Paolo Ghia

Paolo Ghia

Vita-Salute San Raffaele University

Publications: 136

Neil E. Kay

Neil E. Kay

Mayo Clinic

Publications: 128

Tait D. Shanafelt

Tait D. Shanafelt

Stanford University

Publications: 126

Davide Rossi

Davide Rossi

European Society for Medical Oncology

Publications: 123

Thomas J. Kipps

Thomas J. Kipps

University of California, San Diego

Publications: 122

Jan A. Burger

Jan A. Burger

The University of Texas MD Anderson Cancer Center

Publications: 116

Martin Dreyling

Martin Dreyling

Ludwig-Maximilians-Universität München

Publications: 115

Stephan Stilgenbauer

Stephan Stilgenbauer

University of Ulm

Publications: 113

Richard Rosenquist

Richard Rosenquist

Karolinska Institute

Publications: 111

Trending Scientists

Alex Graves

Alex Graves

Google (United States)

John W. Palmour

John W. Palmour

Durham University

Bengt Westermark

Bengt Westermark

Uppsala University

Shin-Han Shiu

Shin-Han Shiu

Michigan State University

Brian Morton

Brian Morton

University of Hong Kong

Michael L. Chikindas

Michael L. Chikindas

Rutgers, The State University of New Jersey

Ariel Lustig

Ariel Lustig

University of Basel

Monica Driscoll

Monica Driscoll

Rutgers, The State University of New Jersey

José M. Palma

José M. Palma

Spanish National Research Council

Poul Erik Jensen

Poul Erik Jensen

University of Copenhagen

Dorothee C. E. Bakker

Dorothee C. E. Bakker

University of East Anglia

Andrew T. Chan

Andrew T. Chan

Harvard University

Martin Gulliford

Martin Gulliford

King's College London

Marc J. van de Vijver

Marc J. van de Vijver

University of Amsterdam

Magda Tsolaki

Magda Tsolaki

Aristotle University of Thessaloniki

Wayne S. DeSarbo

Wayne S. DeSarbo

Pennsylvania State University

Something went wrong. Please try again later.